SCOPUS 정보 검색 플랫폼

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 2, 2009, Pages 72-73

Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer

(1) Coleman, Robert E a

a WESTON PARK HOSPITAL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; GOSERELIN; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER STAGING; DRUG WITHDRAWAL; FRACTURE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; NOTE; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 58849089948 PISSN: 17458366 EISSN: 17458374 Source Type: Journal
DOI: 10.1038/ncpendmet1045 Document Type: Note

Times cited : (4)

References (7)

1
- 20044382779
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status
- Winer EP et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629
- (2005) J Clin Oncol , vol.23 , pp. 619-629
- Winer, E.P.¹

2
- 41949094767
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
- Eastell R et al. (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26: 1051-1057
- (2008) J Clin Oncol , vol.26 , pp. 1051-1057
- Eastell, R.¹

3
- 44649083063
- Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies
- Coleman RE et al. (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 34 (Suppl 1): S31-S42
- (2008) Cancer Treat Rev , vol.34 , Issue.SUPPL. 1
- Coleman, R.E.¹

4
- 49949115926
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
- Gnant M et al. (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9: 840-849
- (2008) Lancet Oncol , vol.9 , pp. 840-849
- Gnant, M.¹

5
- 34247866550
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
- Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822
- (2007) N Engl J Med , vol.356 , pp. 1809-1822
- Black, D.M.¹

6
- 44649187408
- Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
- Reid DM et al. (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34 (Suppl 1): S3-S18
- (2008) Cancer Treat Rev , vol.34 , Issue.SUPPL. 1
- Reid, D.M.¹

7
- 46849110780
- Practical guidance for the management of aromatase inhibitor-associated bone loss
- Hadji P et al. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19: 1407-1416
- (2008) Ann Oncol , vol.19 , pp. 1407-1416
- Hadji, P.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.